Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer

被引:11
作者
Nishimura, Reiki [1 ]
Osako, Tomofumi [1 ]
Okumura, Yasuhiro [1 ]
Nakano, Masahiro [1 ]
Otsuka, Hiroko [1 ]
Fujisue, Mamiko [1 ]
Arima, Nobuyuki [2 ]
机构
[1] Kumamoto Shinto Gen Hosp, Dept Breast Oncol, Kumamoto 8628655, Japan
[2] Kumamoto Shinto Gen Hosp, Dept Pathol, Kumamoto 8628655, Japan
关键词
breast cancer; triple negative; menopausal status; Ki-67; disease-free survival; RECEPTOR; ESTROGEN; EXPRESSION; PATTERNS;
D O I
10.3390/jcm11092331
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification and is the most aggressive subtype, with a heterogeneous genetic profile. The aim of this retrospective study was to evaluate the clinical significance of menopausal status in breast cancer cases with TNBC. Methods: Primary breast cancer patients who underwent curative surgery were enrolled in this retrospective study. A total of 5153 invasive breast cancer cases with Stage I-III were analyzed. The distribution of cases according to the menopausal status and subtypes was investigated and the clinicopathological characteristics and prognosis were compared between pre- and postmenopausal TNBC patients. Results: TNBC was frequently seen in postmenopausal patients and Luminal B and Luminal/HER2 subtypes were more common in premenopausal patients. There was no difference in DFS in the Luminal A/B and HER2 subtypes, but a significant difference was seen in the TNBC patients. Premenopausal patients with TNBC frequently had an overexpression of the p53 protein, a significantly higher Ki-67 index value, and a higher nuclear grade. A multivariate analysis revealed that menopausal status, nodal status, and tumor size were significant factors for DFS in TNBC cases. Conclusion: Menopausal status significantly correlates with breast cancer subtypes. TNBC was often seen in postmenopausal patients and these patients tend to have more favorable factors and a better DFS than premenopausal patients. These findings suggest that menopausal status is an important factor for evaluating biology and prognosis in TNBC cases.
引用
收藏
页数:12
相关论文
共 25 条
[1]  
Aine M, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-021-01392-0
[2]   Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors [J].
Arima, Nobuyuki ;
Nishimura, Reiki ;
Osako, Tomofumi ;
Okumura, Yasuhiro ;
Nakano, Masahiro ;
Fujisue, Mamiko ;
Nishiyama, Yasuyuki ;
Toyozumi, Yasuo .
ONCOLOGY LETTERS, 2019, 17 (01) :616-622
[3]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[4]   Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy [J].
Bonsang-Kitzis, Helene ;
Chaltier, Leonor ;
Belin, Lisa ;
Savignoni, Alexia ;
Rouzier, Roman ;
Sablin, Marie-Paule ;
Lerebours, Florence ;
Bidard, Francois-Clement ;
Cottu, Paul ;
Sastre-Garau, Xavier ;
Lae, Marick ;
Pierga, Jean-Yves ;
Reyal, Fabien .
PLOS ONE, 2015, 10 (12)
[5]   Prognostic role of progesterone receptor expression in a population-based analysis [J].
Caldarella, Adele ;
Barchielli, Alessandro .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (12) :2505-2509
[6]  
Carlson K, 2018, AM SURGEON, V84, P1584
[7]   Menopausal status does not predict Oncotype DX recurrence score [J].
Carr, Danielle N. ;
Vera, Nora ;
Sun, Weihong ;
Lee, Marie Catherine ;
Hoover, Susan ;
Fulp, William ;
Acs, Geza ;
Laronga, Christine .
JOURNAL OF SURGICAL RESEARCH, 2015, 198 (01) :27-33
[8]  
Crozier JA, 2020, LANCET ONCOL, V21, P1611, DOI 10.1016/S1470-2045(20)30538-6
[9]   Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy [J].
Cui, XJ ;
Schiff, R ;
Arpino, G ;
Osborne, CK ;
Lee, AV .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7721-7735
[10]   Triple-negative breast cancer: Clinical features and patterns of recurrence [J].
Dent, Rebecca ;
Trudeau, Maureen ;
Pritchard, Kathleen I. ;
Hanna, Wedad M. ;
Kahn, Harriet K. ;
Sawka, Carol A. ;
Lickley, Lavina A. ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434